{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:28:37Z","timestamp":1785421717598,"version":"3.56.0"},"reference-count":26,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031528","name":"Alfasigma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100031528","id-type":"DOI","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/02n5pfm79","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Hepatic encephalopathy (HE) significantly impairs quality of life (QoL) in patients with cirrhosis. While rifaximin is established in HE treatment and prevention, its specific impact on QoL remains less clearly defined. This systematic review aims to evaluate the effects of rifaximin on QoL in patients with HE. Methods: A comprehensive literature search was conducted in MEDLINE\/PubMed, Embase, and CENTRAL through November 2025. Clinical studies evaluating rifaximin\u2019s impact on QoL in patients with cirrhosis and minimal\/covert or recurrent overt HE were included. Study selection followed PRISMA guidelines. Data extraction focused on study design, population, treatment, and QoL outcomes. Results: Out of 4343 records screened, 10 studies met the inclusion criteria. Several studies evaluated rifaximin in comparison with placebo and focused on patients with minimal or covert HE. Rifaximin was generally associated with improvements in overall and domain-specific QoL scores compared with placebo. These benefits were observed across different dosages and treatment durations. In comparative studies, rifaximin showed QoL outcomes comparable to those of lactulose, L-ornithine L-aspartate, and combination regimens. Conclusions: Rifaximin may be associated with improvements in QoL in patients with cirrhosis and HE, with benefits observed across multiple domains and outcomes broadly comparable to alternative therapies. However, given the limitations of available evidence and the heterogeneity in study designs, HE phenotypes, QoL instruments, and outcome reporting, these findings should be interpreted with caution. Further high-quality comparative trials, particularly in patients with recurrent overt HE and in prophylactic settings, are needed to confirm these findings.<\/jats:p>","DOI":"10.3390\/jcm15145600","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:12:38Z","timestamp":1784257958000},"page":"5600","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quality of Life in Patients with Hepatic Encephalopathy Treated with Rifaximin: A Systematic Review"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9887-7315","authenticated-orcid":false,"given":"Rodolfo","family":"Sacco","sequence":"first","affiliation":[{"name":"Gastroenterology and Digestive Endoscopy Unit, Department of Surgical and Medical Sciences, University of Foggia, Viale Pinto 1, 71122 Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambra","family":"Corti","sequence":"additional","affiliation":[{"name":"Polistudium SRL, 20121 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Giacomelli","sequence":"additional","affiliation":[{"name":"Polistudium SRL, 20121 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2107-2156","authenticated-orcid":false,"given":"Antonio","family":"Facciorusso","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Department of Experimental Medicine, Universit\u00e0 del Salento, 73100 Lecce, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"ref_1","first-page":"CD011585","article-title":"Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis","volume":"7","author":"Zacharias","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Hu, Y., Zhang, X., Xiao, Y., Wu, Z., and Wang, Y. (2025). Efficacy and safety of rifaximin in preventing hepatic encephalopathy: A systematic review and meta-analysis. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0323359"},{"key":"ref_3","first-page":"58","article-title":"Evaluating Clinical Outcomes of Adjunct Rifaximin Therapy in Patients with Overt Hepatic Encephalopathy: A Prospective Randomized Study","volume":"15","author":"Alazazzi","year":"2025","journal-title":"Euroasian J. Hepatogastroenterol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Kawaratani, H., Namisaki, T., Kondo, Y., Tatsumi, R., Kawabe, N., Tanabe, N., Sakamaki, A., Hoshikawa, K., Uchida, Y., and Endo, K. (2025). Real-World Setting of Efficacy and Safety of 3 Years of Rifaximin Administration in Japanese Patients with Hepatic Encephalopathy: A Multicenter Retrospective Study. J. Clin. Med., 14.","DOI":"10.3390\/jcm14041358"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3748\/wjg.v29.i1.144","article-title":"Role of gut microbiota in the pathogenesis and therapeutics of minimal hepatic encephalopathy via the gut-liver-brain axis","volume":"29","author":"Luo","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e39905","DOI":"10.1097\/MD.0000000000039905","article-title":"Efficacy and safety of rifaximin for the prophylaxis of hepatic encephalopathy: A meta-analysis","volume":"104","author":"Huang","year":"2025","journal-title":"Medicine"},{"key":"ref_7","first-page":"e86193","article-title":"Therapeutic duel of rifaximin versus lactulose in hepatic encephalopathy: A systematic review","volume":"17","author":"Oriko","year":"2025","journal-title":"Cureus"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jhep.2021.09.010","article-title":"Rifaximin-\u03b1 reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial","volume":"76","author":"Patel","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2147\/TCRM.S425292","article-title":"Rifaximin alfa and liver diseases: More than a treatment for encephalopathy, a disease modifier","volume":"19","author":"Torre","year":"2023","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jhep.2022.06.001","article-title":"EASL Clinical Practice Guidelines on the management of hepatic encephalopathy","volume":"77","author":"Montagnese","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"284","DOI":"10.14309\/ajg.0000000000002008","article-title":"Systematic Review and Meta-Analysis on the Effects of Lactulose and Rifaximin on Patient-Reported Outcomes in Hepatic Encephalopathy","volume":"118","author":"Moon","year":"2023","journal-title":"Am. J. Gastroenterol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/ajg.2010.455","article-title":"Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial)","volume":"106","author":"Sidhu","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1365-2036.2011.04808.x","article-title":"Randomised clinical trial: Rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy\u2014A double-blind placebo-controlled study","volume":"34","author":"Sanyal","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1053\/j.gastro.2010.08.061","article-title":"Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy","volume":"140","author":"Bajaj","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/MEG.0000000000000786","article-title":"Improvement of sleep architecture parameters in cirrhotic patients with recurrent hepatic encephalopathy with the use of rifaximin","volume":"29","author":"Bruyneel","year":"2017","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_16","first-page":"1099","article-title":"Effects of low-dose and high-dose rifaximin in the treatment of covert hepatic encephalopathy","volume":"10","author":"Tan","year":"2022","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Bakulin, I.G., Ivanova, K.N., Eremina, E.Y., Marchenko, N.V., and NORMIND study team (2023). Comparative analysis of the efficacy of different regimens of 12 months rifaximin-alfa therapy in patients with liver cirrhosis and minimal hepatic encephalopathy. Diagnostics, 13.","DOI":"10.3390\/diagnostics13203239"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/liv.12921","article-title":"Rifaximin vs. lactulose in treatment of minimal hepatic encephalopathy","volume":"36","author":"Sidhu","year":"2016","journal-title":"Liver Int."},{"key":"ref_19","first-page":"154","article-title":"#P-0687 Challenges in treatment of minimal hepatic encephalopathy","volume":"32","author":"Elnoemany","year":"2017","journal-title":"J. Gastreonterol Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/jhbp.947","article-title":"Nitazoxanide versus rifaximin in preventing the recurrence of hepatic encephalopathy: A randomized double-blind controlled trial","volume":"28","author":"Glal","year":"2021","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.jceh.2023.07.303","article-title":"Comparative study of rifaximin vs lactulose on minimal hepatic encephalopathy, an open label randomized trial","volume":"13","year":"2023","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin treatment in hepatic encephalopathy","volume":"362","author":"Bass","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.cgh.2013.12.021","article-title":"Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy","volume":"12","author":"Mullen","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/DDDT.S172324","article-title":"Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy","volume":"13","author":"Wang","year":"2018","journal-title":"Drug Des. Devel Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e000531","DOI":"10.1136\/bmjgast-2020-000531","article-title":"Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): A multicentre randomised, double blind, placebo controlled trial (PEARL trial)","volume":"7","author":"Schaapman","year":"2020","journal-title":"BMJ Open Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5600\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:16:35Z","timestamp":1784607395000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":26,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15145600"],"URL":"https:\/\/doi.org\/10.3390\/jcm15145600","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]}}}